S&P 500   3,375.76 (+0.07%)
DOW   27,945.28 (+0.17%)
QQQ   272.01 (-0.17%)
AAPL   457.61 (-0.53%)
MSFT   208.69 (+0.00%)
FB   260.66 (-0.24%)
GOOGL   1,510.13 (-0.43%)
AMZN   3,143.11 (-0.57%)
NVDA   460.00 (+0.50%)
CGC   17.24 (-0.46%)
BABA   252.38 (-0.53%)
TSLA   1,637.37 (+1.01%)
GE   6.65 (+0.76%)
MU   46.01 (-0.28%)
AMD   80.94 (-1.10%)
T   30.05 (+0.47%)
F   7.08 (+0.71%)
ACB   10.83 (+6.39%)
GILD   68.67 (+0.72%)
NFLX   481.65 (+0.07%)
DIS   130.37 (-0.45%)
BAC   26.56 (+0.80%)
BA   177.49 (+1.58%)
S&P 500   3,375.76 (+0.07%)
DOW   27,945.28 (+0.17%)
QQQ   272.01 (-0.17%)
AAPL   457.61 (-0.53%)
MSFT   208.69 (+0.00%)
FB   260.66 (-0.24%)
GOOGL   1,510.13 (-0.43%)
AMZN   3,143.11 (-0.57%)
NVDA   460.00 (+0.50%)
CGC   17.24 (-0.46%)
BABA   252.38 (-0.53%)
TSLA   1,637.37 (+1.01%)
GE   6.65 (+0.76%)
MU   46.01 (-0.28%)
AMD   80.94 (-1.10%)
T   30.05 (+0.47%)
F   7.08 (+0.71%)
ACB   10.83 (+6.39%)
GILD   68.67 (+0.72%)
NFLX   481.65 (+0.07%)
DIS   130.37 (-0.45%)
BAC   26.56 (+0.80%)
BA   177.49 (+1.58%)
S&P 500   3,375.76 (+0.07%)
DOW   27,945.28 (+0.17%)
QQQ   272.01 (-0.17%)
AAPL   457.61 (-0.53%)
MSFT   208.69 (+0.00%)
FB   260.66 (-0.24%)
GOOGL   1,510.13 (-0.43%)
AMZN   3,143.11 (-0.57%)
NVDA   460.00 (+0.50%)
CGC   17.24 (-0.46%)
BABA   252.38 (-0.53%)
TSLA   1,637.37 (+1.01%)
GE   6.65 (+0.76%)
MU   46.01 (-0.28%)
AMD   80.94 (-1.10%)
T   30.05 (+0.47%)
F   7.08 (+0.71%)
ACB   10.83 (+6.39%)
GILD   68.67 (+0.72%)
NFLX   481.65 (+0.07%)
DIS   130.37 (-0.45%)
BAC   26.56 (+0.80%)
BA   177.49 (+1.58%)
S&P 500   3,375.76 (+0.07%)
DOW   27,945.28 (+0.17%)
QQQ   272.01 (-0.17%)
AAPL   457.61 (-0.53%)
MSFT   208.69 (+0.00%)
FB   260.66 (-0.24%)
GOOGL   1,510.13 (-0.43%)
AMZN   3,143.11 (-0.57%)
NVDA   460.00 (+0.50%)
CGC   17.24 (-0.46%)
BABA   252.38 (-0.53%)
TSLA   1,637.37 (+1.01%)
GE   6.65 (+0.76%)
MU   46.01 (-0.28%)
AMD   80.94 (-1.10%)
T   30.05 (+0.47%)
F   7.08 (+0.71%)
ACB   10.83 (+6.39%)
GILD   68.67 (+0.72%)
NFLX   481.65 (+0.07%)
DIS   130.37 (-0.45%)
BAC   26.56 (+0.80%)
BA   177.49 (+1.58%)
Log in

NASDAQ:PDLIPDL BioPharma Stock Price, Forecast & News

$3.31
+0.03 (+0.91 %)
(As of 08/14/2020 01:25 PM ET)
Add
Compare
Today's Range
$3.26
Now: $3.31
$3.31
50-Day Range
$2.71
MA: $3.01
$3.51
52-Week Range
$2.06
Now: $3.31
$3.86
Volume9,975 shs
Average Volume1.23 million shs
Market Capitalization$377.28 million
P/E RatioN/A
Dividend YieldN/A
Beta0.87
PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in the United States, Europe, and internationally. The company operates in three segments: Pharmaceutical, Medical Devices, and Income Generating Assets. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures, markets, and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Read More
PDL BioPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.97 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:PDLI
CUSIP69329Y10
Phone775-832-8500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.76 million
Cash Flow$0.47 per share
Book Value$5.20 per share

Profitability

Net Income$-70,410,000.00

Miscellaneous

Employees105
Market Cap$377.28 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$3.31
+0.03 (+0.91 %)
(As of 08/14/2020 01:25 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PDLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions

How has PDL BioPharma's stock been impacted by Coronavirus?

PDL BioPharma's stock was trading at $3.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PDLI shares have increased by 7.8% and is now trading at $3.31.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of PDL BioPharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for PDL BioPharma
.

When is PDL BioPharma's next earnings date?

PDL BioPharma is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for PDL BioPharma
.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma Inc (NASDAQ:PDLI) announced its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.10 by $0.53. The biotechnology company earned $5.21 million during the quarter.
View PDL BioPharma's earnings history
.

How will PDL BioPharma's stock buyback program work?

PDL BioPharma announced that its Board of Directors has initiated a share buyback plan on Monday, September 24th 2018, which permits the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 27.3% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board believes its stock is undervalued.

What price target have analysts set for PDLI?

1 Wall Street analysts have issued 1-year target prices for PDL BioPharma's shares. Their forecasts range from $3.00 to $3.00. On average, they expect PDL BioPharma's stock price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 9.4%.
View analysts' price targets for PDL BioPharma
.

Has PDL BioPharma been receiving favorable news coverage?

News stories about PDLI stock have been trending somewhat negative recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. PDL BioPharma earned a daily sentiment score of -1.6 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about PDL BioPharma
.

Are investors shorting PDL BioPharma?

PDL BioPharma saw a increase in short interest in June. As of June 30th, there was short interest totaling 11,130,000 shares, an increase of 82.2% from the June 15th total of 6,110,000 shares. Based on an average trading volume of 1,090,000 shares, the days-to-cover ratio is presently 10.2 days. Currently, 10.1% of the company's shares are sold short.
View PDL BioPharma's Short Interest
.

Who are some of PDL BioPharma's key competitors?

What other stocks do shareholders of PDL BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), AT&T (T), Opko Health (OPK), Canopy Growth (CGC), Advanced Micro Devices (AMD), Novavax (NVAX), General Electric (GE), Teva Pharmaceutical Industries (TEVA) and Bank of America (BAC).

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the following people:
  • Mr. Dominique P. Monnet, CEO, Pres & Director (Age 58)
  • Mr. Peter S. Garcia, VP & CFO (Age 57)
  • Mr. Christopher L. Stone, VP, Gen. Counsel & Sec. (Age 55)
  • Mr. Nathan Kryszak, Deputy Gen. Counsel & Assistant Sec.

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

Who are PDL BioPharma's major shareholders?

PDL BioPharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Brandes Investment Partners LP (4.70%), Ancora Advisors LLC (1.49%), Goldman Sachs Group Inc. (1.28%), Grantham Mayo Van Otterloo & Co. LLC (0.97%), WINTON GROUP Ltd (0.74%) and Russell Investments Group Ltd. (0.62%).
View institutional ownership trends for PDL BioPharma
.

Which major investors are selling PDL BioPharma stock?

PDLI stock was sold by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP, Principal Financial Group Inc., West Family Investments Inc., Ancora Advisors LLC, UBS Group AG, Hancock Whitney Corp, Alps Advisors Inc., and SG Americas Securities LLC.
View insider buying and selling activity for PDL BioPharma
.

Which major investors are buying PDL BioPharma stock?

PDLI stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Context Capital Management LLC, Prudential Financial Inc., WINTON GROUP Ltd, Grantham Mayo Van Otterloo & Co. LLC, JBF Capital Inc., Rafferty Asset Management LLC, and Archetype Wealth Partners LLC.
View insider buying and selling activity for PDL BioPharma
.

How do I buy shares of PDL BioPharma?

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDLI stock can currently be purchased for approximately $3.31.

How big of a company is PDL BioPharma?

PDL BioPharma has a market capitalization of $377.28 million and generates $54.76 million in revenue each year. The biotechnology company earns $-70,410,000.00 in net income (profit) each year or $0.28 on an earnings per share basis. PDL BioPharma employs 105 workers across the globe.

What is PDL BioPharma's official website?

The official website for PDL BioPharma is www.pdl.com.

How can I contact PDL BioPharma?

PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.